Nov 15 (Reuters) – The US FDA on Sunday declined to approve Summit Therapeutics' lung cancer drug, dealing a setback to the efforts to bring a new treatment for patients who have limited options after
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)